FDA Inspection 1310476 — Central Pennsylvania Blood Bank
The FDA completed an inspection of Central Pennsylvania Blood Bank on Mar 11, 2026 in Ephrata, PA. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Biologics.
Inspection details
- Classification
- No Action Indicated (NAI)
- End Date
- Mar 11, 2026
- Fiscal Year
- 2026
- Product Type
- Biologics
- Project Area
- Blood and Blood Products
- Location
- Ephrata, PA (United States)